Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. - Loor A; Mack KN; Bauer D; Ingham A; Pratt EC; Lewis JS (European journal of nuclear medicine and molecular imaging, 2026)